The document discusses the challenges and opportunities in treating rheumatoid arthritis (RA). It notes that early diagnosis and treatment are important as joint erosions can occur early in RA. It also discusses the criteria for diagnosing RA and shows that biologic disease-modifying antirheumatic drugs (DMARDs) like etanercept and adalimumab, when combined with methotrexate, provide efficacy in reducing the signs and symptoms of RA as well as improving physical function. However, it notes there are safety considerations to monitor with biologic DMARDs such as infections, malignancies, and demyelination.